Feeds:
Posts
Comments

Posts Tagged ‘Wall Street Journal’

WALL STREET JOURNAL: A new study raises the question of whether patients facing prostate screening and their health-care professionals are engaging in shared decision making, and what such a collaboration should look like. READ MORE>

Read Full Post »

WALL STREET JOURNAL: Dendreon Corp expects to file for marketing approval for advanced prostate cancer immunotherapy treatment Provenge in mid-November and hopes to get final FDA approval in the middle of next year. READ MORE>

NEW PROSTATE CANCER INFOLINK: It is worth remembering that Provenge is not a “drug” in any normal sense of the term. READ MORE>

Provenge is strictly a form of individual cell-based immunotherapy in which cells from the patient’s own body are extracted, modified, and then re-infused back into the patient.

Every single dose of Provenge therefore has to be individually created.

PROSTABLOG NZ: The pressure on NZ’s drug approval organisation, Pharmac, to fast-track Provenge to Kiwi patients is shaping to be another Herceptin debate.

In that case, it seems only a very loud and effective campaign by sufferers succeeded in getting the expensive breast cancer treatment past Pharmac’s drug subsidisation process.

If Provenge has to be individually manufactured for each patient, you can bet the doses will cost thousands of dollars.

Pharmac may be spared the dilemma beyond next year, since it seems the manufacturer will not be able to fulfill the demand in the US, let alone other countries.

Read Full Post »

PROSTABLOG NZ: When global mainstream media reported the recent (partial) success of Dendreon drug company getting FDA approval for its new immunotherapy prostate cancer drug, Provenge, they didn’t mention how makers of a now-discredited rival drug may have delayed its path to chemist shops.

An “alternative” market investors’ website called Market Rap.com has just published a story by a former Wall Street Journal journalist that purports to reveal a murky background to what might be called – if it’s all, even partly, true – one of America’s biggest drug scandals.

It involves the US prostate Cancer Foundation (no relation to NZ’s) and its ubiquitous chairman, Michael Milken, who featured recently on the Larry King Live special about prostate cancer.

If you’ve got lots of time, READ MORE>

Read Full Post »

JULY 8: WALL STREET JOURNAL:  President Obama may be pushing the US towards a “medical-rationing” system like that in the UK, administered by the National Institute for Health and Clinical Excellence, or NICE. This will have consequences:

The Concord study published in 2008 showed that cancer survival rates in Britain are among the worst in Europe. Five-year survival rates among US cancer patients are also significantly higher than in Europe: 84% vs. 73% for breast cancer, 92% vs. 57% for prostate cancer. While there is more than one reason for this difference, surely one is medical innovation (discouraged by the NICE approach) and the greater US willingness to re-imburse for it.  READ MORE>

Read Full Post »

The Man, the Gland, the Dilemmas

YOU’VE been getting annual blood tests to check for prostate cancer.

But two big studies in the New England Journal of Medicine just found that screening for PSA — prostate specific antigen — doesn’t save many lives.

Should you keep checking it?…

So begins a recent two-part series in the Wall Street Journal. Click HERE to read Part 1. Click HERE to read Part 2, which includes a useful charts comparing treatment options.

Read Full Post »